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weight. The main objective is to conduct a pharmacoeconomic analysis to find out
the cost effectiveness of Diethylpropion with diet and exercise. (DEPDaE), com-
pared against Diet and Exercise (DaE) inMexico.METHODS:Thepoint of viewof the
study was the supplier of IMSS health services. The target population were men
andwomen over 18 years with BMI30 kg/m2. Outcomemeasures were the reduc-
tion of weight in kg and Quality Adjusted Life Years (QALYs). The direct costs in the
treatment of obesity were assessed, treatment of adverse events and complica-
tions (Type 2 Diabetes Mellitus and cardiovascular disease). We used a Dynamic,
Stochastic DiscreteModel (DSD) and a univariate and probabilistic sensitivity anal-
ysis was performed. All the quantities expresed in Mexican pesos (MXP) RESULTS:
DEPDaE presented a lower cost and improved the utility and effectiveness when
compared DaE. Incremental cost was $18,361MXP in males and $16,285MXP in
women. Incremental effectiveness and utility was 4.19 kg and 0.10 QALYs in men
and 3.77 kg and 0.08 QALYs in women. ICER pointed the absolute dominance for
DEPDaE. Estimated savings per 100 patients in the IMSS can be $1,697,027MXP if
complemented by a 100% change health habits using DEPDaE. CONCLUSIONS:
The combination of DEPDaE provides a cost effective improvement to the treat-
ment of patients with a risk profile for obesity.
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OBJECTIVES: Fludarabine (F) is amainstay treatment for CLL. Despite the availabil-
ity of an oral formulation with equivalent efficacy and improved patient accept-
ability, many centres use an IV generic formulation assuming it is cheaper. A
cost-minimisation analysis was undertaken on the two formulations. METHODS:
The model assessed oral vs IV F and combination with oral/IV cyclophosphamide
(FC). It included: European acquisition values defaulted to generic prices; body
surface area 1.75m2; mg/m2 dosages oral F 40, IV F 25, oral C 150, IV C 250; dosage
days/cycle F 5 / FC 3 for 6 cycles/patient. Published adverse events rates were
equivalent except for IV administration complications (8% default) and diarrhoea
(oral F 34.6% vs IV F 11.3% Grade 1/2 and 3.8% vs 0%  Grade 3/4)  2% managed
in hospital. Equipment and clinical resource costs were defaulted to published
rates and authors’ centres. A sensitivity analysis assessing minimum and maxi-
mum potential costs was applied. RESULTS: Acquisition costs per treatment
coursewere higher for oral vs IV (F - €5,334 vs €1,313 FC - €3,213.16 vs €894). However
IV costs increased with adverse events (oral vs IV complications mean €0 vs €40,
diarrhoea €1 vs €0) and hospital resource costs (oral vs IV F - €18 vs €4,200, FC- €18
vs €2,520). Direct oral vs IV treatment costs per patient were F - €5,353 vs €5,553
(range €5,334-€5,353 and €5,513-€5,577), FC - €3,232 vs €3,454 (range €3,214-€3,233
and €3,414-€3,478). Modelling oral adoption in 100 patients - 80% IV F / 20% IV FC, a
100% and 90% switch respectively resulted in €19,943 mean cost savings, releasing
funding and resources for improved care and patient throughput. CONCLUSIONS:
Oral fludarabine acquisition costs are higher than generic IV, but cost-minimisa-
tionmodelling demonstrated reduced direct costs with oral fludarabine, while also
being preferred by patients.
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OBJECTIVES: Recent randomized trials (RCT) have suggested erythropoiesis stim-
ulating agents (ESA) reduce mortality in critically ill trauma patients; however ESA
are costly. We sought to determine cost-effectiveness of ESA in this patient
population.METHODS: A decision analytic model was constructed to compare the
use of ESA to standard care in trauma patients admitted to an intensive care set-
ting. Base case costs and benefits at one year were estimated using mortality esti-
mates from available RCTs. One way and probabilistic sensitivity analyses were
conducted for comparison of the base case scenario with 10 and 25 year time
horizons inMarkovmodels.RESULTS: ESAusewas associatedwith a cost per QALY
gained of $74,500 to $81,748 compared with standard care at one year. One-way
sensitivity analyses indicated results were sensitive to changes in mortality risk,
risk of thrombosis, relative risk ofmortality, relative risk of thrombosis, and quality
of life estimates. Cost effectiveness acceptability curves generated from probabi-
listic sensitivity analysis indicated that the probability ESA would be considered
attractive ranged from 35% to 80% over the range of WTP of $60,000 to $120,000.
Consideration of longer time horizons reduced the cost per QALY gained to $9,338 
$5,957. CONCLUSIONS:While the cost per QALY gained with ESA use falls into the
range of currently accepted healthcare technologies funded in Canada, significant
uncertainty exits, particularly long-term survival benefit with ESA use. Further
research into the efficacy and safety of ESA use in critically ill trauma patients is
required prior to widespread use.
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OBJECTIVES: To examine cost-utility of different erythropoietins (epoetin alfa and
epoetin beta) in Russian anemic patients on dialysis.METHODS: Health survey of
patients in dialysis departments of 23 regions. About 1400 questionnaires were
distributed in May - June 2010. Health-related quality of life was assessed with
self-administrated validated version of Russian version of Euroqol-5D question-
naire. Inclusion criteria were age older than 18 years, terminal stage of chronic
renal failure and treatment with dialysis more then 4 months. All patients have
been divided on four subgroups depending on the name of received erythropoietin.
Direct cost contains of cost of erythropoietin, administration cost, cost of iron
supplemention was calculated. RESULTS: 1395 completed questionnaires were re-
ceived by September, 2010. Detailed analysis of antianemic therapy has shown that
85% patients received erytropoetins. There were four the most used drugs: Recor-
mon (epoetin beta) (42%), Eralfon (epoetin alfa) (18%), Epocrinum (epoetin alfa)
(16%), Eprex (epoetin alfa) (9%). Groups were not differ according to the level of
hemoglobin. Average HRQL, assessed with VAS, was not differ significantly be-
tween 4 groups: 0.62 for Eralfon, 0.59 for Recormon, 0.585 for Eprex, 0.56 for Epoc-
rinum. Per year cost of treatment with Eprex was 5 382 USD, with Eralfon – 4 463
USD, with Recormon – 4 204 USD, with Epocrinum – 1 652 USD. Lifelong costs of
treatment with Eprex was 50 017 USD, with Eralfon – 49 098 USD, with Recormon –
48 785 USD, with Epocrinum – 46 596 USD. The cost per QALY was 85 499 USD per
QALY for Eprex, 83 505 USD per QALY for Epocrinum, 82 547 USD per QALY for
Recormon and 75 596 USD per QALY for Eralfon. CONCLUSIONS: Present cost-
utility analyses revealed that in Russian anemic patients on dialysis the most
cost-effective strategy of antianemic therapy among 4 common erythropoietins
was Eralfon with 75 596 USD per QALY.
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OBJECTIVES: Inflammatory Bowel Disease (IBD) is an immune-mediated inflam-
matory disorder which includes Crohn’s disease and ulcerative colitis. The rela-
tionship betweenout-of-pocket (OOP) healthcare costswith productivity is notwell
known in IBD. This study explores the relationship of OOP healthcare costs on
productivity. METHODS: Participants self-identified with IBD and aged 18 com-
pleted an internet-based cross-sectional survey in 1Q2009. Self-reported produc-
tivity loss including absenteeism, presenteeism, overall work impairment and ac-
tivity impairment expressed as impairment percentages, were measured by the
Work Productivity andActivity Impairment questionnaire. Participantswere asked
about IBD-related and overall monthly OOP healthcare costs. Negative binomial
regression models were developed to adjust for age, gender, ethnicity, income,
education, and marital status. RESULTS: 534 participated, 67% were female, 55%
were employed, and 13% were on short- and long-term disability. More than half
(53%) reported annual household incomes between $50-100K, 40% were college
educated. Overall OOP costs were: $0-$50 for 52.6%, $51-$100 for 18.2%, $101-$200
for 15.5%, and  $200 for 13.7%. Among employed, rates of absenteeism, presen-
teeism, and overall work impairment were 9.97%, 16.3% and 20.0%, respectively.
43.2% reported impairment in daily activities. Significantly greater productivity
loss (presenteeism, b 2.79, p 0.0004) and overall work impairment (b 2.78, p
0.0006) were observed among patients with overall OOP costs $200, as compared
to those with OOP costs between $0-50 after adjusting for patient demographics.
CONCLUSIONS: Higher monthly OOP costs were associated with higher work im-
pairment and lower productivity. Shifting healthcare costs to employees maybe
associated with productivity loss. Further research is needed to determine longer-
term impact of OOP healthcare costs on work productivity.
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OBJECTIVES: Hyponatremia (HN) is the leading electrolyte abnormality among
hospitalized patients. In the absence of symptoms, HN is often overlooked as a
condition that warrants aggressive intervention. Though HN is common, little is
known regarding the influence of HN on patient outcomes and healthcare resource
utilization. This study assessed the impact of HN on inpatient total and intensive
care unit (ICU) cost, total and ICU length of stay (LOS), likelihood of ICU admission,
and 30-, 90-, and 180-day readmission. METHODS: Premier’s Perspective® data-
base was utilized to construct a stratified sample of hospital inpatients discharged
between January 1, 2007 and June 30, 2009. HN patients were identified using pri-
mary or secondary diagnosis of HN (n558,815) and were matched to a non-HN
control group (n558,815) using exact matching of age, gender, provider region,
and 3M™ APR-DRG assignment. Matching was further refined using propensity
scores based on additional patient and hospital characteristics and patient comor-
bidities. Cost was analyzed using a multivariate general linear regression model
with gammadistribution and log-link, LOSwith negative binomial distribution and
log-link, and ICU admission and hospital readmission with multivariate logistic
regression. RESULTS: In contrast to non-HN patients, patients with HN had signif-
icantly higher total inpatient cost (9.49%, CI8.99-10.00; p.0001), ICU cost (9.12%;
CI8.04-10.23; p.0001), total LOS (12.24%, CI11.85-12.64; p.0001), and ICU LOS
(11.06%, CI9.60-12.54; p.0001). HN patients were significantly more likely to be
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